DOCSLIB.ORG

Acquisitions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acquisitions MERGERS & ACQUISITIONS Unrivaled Experience in Global M&A Transactions ROPES & GRAY MERGERS & ACQUISITIONS ROPES & GRAY’S global M&A team can handle any Recognized as a leader, our M&A practice group deal, in any industry sector, anywhere in the world. possesses both extensive transaction experience and With over 150 M&A attorneys, we have the knowl- deep industry knowledge, providing unrivaled counsel edge, track record and resources to help clients succeed. on a full range of strategic transactions. WHAT WE DO OUR TRACK RECORD We regularly advise on mergers and acquisitions, joint ventures, n PFIZER strategic alliances, securities offerings, and other capital-raising Represented Pfizer, a global pharmaceutical activities, including: company, in its $17 billion acquisition of Hospira. n Acquisitions and dispositions n Mezzanine debt and high yield n bond financing Equity financing n CUBIST PHARMACEUTICALS n n Management compensation Structured financing Represented Cubist Pharmaceuticals Inc. n n Senior debt financing Minority investments in its proposed $9.5 billion sale to Merck n Seller financing & Co. Inc., a provider of various health solutions. n SYNAGEVA BIOPHARMA WHO WE SERVE Representing Synageva BioPharma in its Many of the world’s largest and most well-known public and private proposed $8.4 billion sale to Alexion Phar- companies, private equity funds, and financial institutions rely on maceuticals, a biopharmaceutical company. our counsel. Representative clients include: n PAR PHARMACEUTICALS Representing Par Pharmaceuticals in its n AbbVie Inc. n Hanover Insurance Group proposed $8.05 billion sale to Endo Inter- n Acceleron Pharma Inc. n IMS Health national, an Ireland-based pharmaceutical n Affiliated Managers Group n Ironwood Pharmaceuticals company. n Alexion n Katy Industries, Inc. Pharmaceuticals Inc. n TORNIER n LPL Financial Holdings Representing Wright Medical Group in its n Bain Capital n MicroVision, Inc. $3.3 billion cross-border merger of equals n Becton, Dickinson and Co. n NetEase.com, Inc. with Amsterdam-based Tornier N.V., a n Cambrex n Novavax, Inc. global medical device company. n Carter’s n Planet Fitness n FOCUS MEDIA n Covidien Plc n Samsonite Represented China Everbright in its $3.7 n Domino’s Pizza International S.A. billion go-private transaction for Focus n Dunkin’ Brands n State Street Corporation Media, a digital media company. n Emcor Group, Inc. n Symmetry Medical Inc. n NSTAR n Eversource Energy n The TJX Companies, Inc. Represented NSTAR in its merger with n Keurig Green Mountain n TPG Capital Northeast Utilities, which created one of n GT Advanced Technologies n TransAct Technologies the nation’s largest utilities, with an enter- prise value totaling $17.5 billion. CROSS-PRACTICE COLLABORATION Ropes & Gray attorneys focus on the most critical business needs of our clients, across a range of leading legal practices. Our collaborative approach means that our clients have ready access to the knowledge and experience of attorneys in all relevant practice areas. Intellectual Financing & Environmental FCPA Property Restructuring Labor & Employment/ Life Sciences Securities Executive Compensation Health Care Real Estate Private Equity Tax n DEMOULAS SUPERMARKETS INC. Represented The Strategic Alternative MARKET PERCEPTION Special Committee of the Board of Directors of Demoulas Super Markets n M&A Advisor n The American Lawyer Inc. in a $1.6 billion deal that enabled Named “Law Firm of the Year” Global Legal Awards minority shareholders to purchase a for international M&A in 2015. Honored for “Global M&A Deal of the Year” in the “Latin America/ 50.5 percent stake in the company. n Chambers Mexico” and “China Private Eq- Ranked as a leading corporate/ n ENTEGRIS, INC. uity” categories in 2014. M&A practice in the U.S., Asia, Represented Entegris, Inc. in its $1.15 China, Japan and Korea. n International M&A billion acquisition of ATMI Inc., a Advisor Awards supplier of semiconductor materials. n The Legal 500 Recognized for “M&A Deal Ranked for private equity transac- of the Year (Over $100 million n PARTY CITY HOLDINGS tions in the U.S., U.K., Hong to $250 million)” in 2014. Represented Party City Holdings in its Kong and China. $2.69 billion sale to Thomas H. Lee n PrivCo Top 20 Law Firms n U.S. News & World Report – Partners, a private equity firm. for Private Tech M&A Best Lawyers Transactions Ranked in the top tier for M&A n VIRGIN MEDIA Ranked in the top 10 in the law; named “Law Firm of the U.S. in 2014. Represented Liberty Global in the Year’ for “Leveraged Buyouts financing of the $24 billion acquisition and Private Equity Law” and n Bloomberg Global M&A of Virgin Media. for “Private Funds/Hedge Funds Legal Advisory Ranking Law” in 2015. Ranked (by volume) among the n THE TIMBERLAND COMPANY top 20 firms by private equity Represented The Timberland Company, n IFLR1000 deals announced in 2014. a footwear company, in its $2.23 billion Ranked for M&A in the U.S., China, Hong Kong and Japan, and n sale to V.F. Corporation. Law360 for private equity transactions in Named a private equity n GENZYME CORPORATION the U.K. “Practice of the Year” in 2013. Represented Genzyme Corporation in n IFLR Asia Awards n China Law & Practice Awards Sanofi’s acquisition of the biotechnology Recognized for “Private Equity Honored for “Private Equity Deal firm for $20.1 billion in cash, plus Deal of the Year” in 2014. of the Year” in 2014. contingent value rights. ROPES & GRAY MERGERS & ACQUISITIONS GLOBAL REACH Ropes & Gray serves clients through a global network of offices in the world’s major centers of business, finance, technology and government. Across 17 time zones, more than 1,100 attorneys based in the United States, Europe and Asia collaborate seamlessly to provide clients with the high-quality representation and uncompromising, round-the-clock service that have made Ropes & Gray one of the world’s premier law firms. “They have a really high-quality team and a deep bench. I get outstanding service and outstanding minds.” —Client Chambers USA GLOBAL CONTACTS Jane Goldstein James Lidbury Practice Group Leader Practice Group Leader New York & Boston Hong Kong [email protected] [email protected] New York: + 1 212 596 9230 +852 3664 6521 Boston: + 1 617 951 7431 Carl Marcellino Arthur Mok Practice Group Leader Partner New York Shanghai [email protected] [email protected] + 1 212 841 0623 + 86 21 6157 5288 HONGHONG KONG KONG | SHANGHAI | SEOUL | SEOULSHANGHAI | TOKYO | TOKYO NEWNEW YORK YORK | |WASHINGTON, WASHINGTON, D.C. D.C. | |BOSTON BOSTON | |LONDON LONDON CHICAGOCHICAGO | SAN | SAN FRANCISCO FRANCISCO | SILICON | SILICON VALLEY VALLEY ropesgray.com © 2015 Ropes & Gray LLP. All rights reserved. Prior results do not guarantee a similar outcome. Communicating with Ropes & Gray LLP or a Ropes & Gray lawyer does not create a client-lawyer relationship. 15_0460.
Load more

Recommended publications
  • Resource #350932
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2019 ~ Resource #350932 Anticipated Availability of First-Time Generics ―To help explain the benefits of generic drugs to your patients, the FDA has patient education materials available at https://www.fda.gov/drugs/generic-drugs/patient-education ― Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Acanya Benzoyl peroxide 2.5%/ Teva Generic now available (Valeant) Clindamycin phosphate 1.2% Cuprimine Penicillamine capsule Amerigen, Teva Generic now available (Bausch Health) Delzicol Mesalamine delayed-release Teva Generic now available (Warner Chilcott) capsule Diclegis Doxylamine/Pyridoxine Teva Generic now available (Duchesnay) Exjade Deferasirox tablets for oral Teva Generic now available (Novartis) suspension Fareston Toremifene Rising (EirGen Pharma Limited) Generic now available (Kyowa Kirin) Faslodex Fulvestrant Sandoz Generic now available (AstraZeneca) Firazyr Icatibant Teva Generic now available (Shire Orphan Therapies) Gablofen Baclofen 1 mg/mL single dose Mylan Institutional Generic now available (Piramal) vial Hemabate Carboprost tromethamine Dr. Reddy’s Generic now available (Pharmacia & Upjohn) Letairis Ambrisentan Cipla, Mylan, Par, Sigmapharm, Sun, Teva, Generic now available (Gilead) Zydus Lexiva Fosamprenavir Mylan Generic now available (Viv) More. Copyright © 2019 by Therapeutic Research Center 3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 pharmacist.therapeuticresearch.com ~ prescriber.therapeuticresearch.com ~ pharmacytech.therapeuticresearch.com ~ nursesletter.therapeuticresearch.com (Clinical Resource #350932: Page 2 of 24) Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Lotemax Loteprednol ophthalmic Hi-tech Generic now available (Bausch & Lomb) suspension Lyrica Pregabalin capsule Alembic, Amneal, Ascend (Alkem), Cipla Generic now available (PF Prism CV) (InvaGen), Dr.
    [Show full text]
  • Gilead Sciences, Inc. November 13, 2016
    Student Investment Management Gilead Sciences, Inc. November 13, 2016 Gilead Sciences, Inc. NASDAQ: GILD BUY $92.00 The Fisher College of Business Student Investment Management Program is initiating coverage on Gilead Sciences with a BUY rating. Our target price is $92.00. Our implied P/E for 2016E is 7.9x versus consensus 6.5x. Our 2017 and 2018 estimates are 8.8x and 9.5x, respectively. Company overview Gilead Sciences, Inc. is a research-based biopharmaceutical Fund Manager company that discovers, develops and commercializes innovative Royce West, CFA medicines in areas of unmet medical need. Gilead strives to 614-227-2948 transform and simplify care for people with life-threatening illnesses [email protected] around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver Analyst diseases, cancer, inflammatory and respiratory diseases, and Andrew Jasen cardiovascular conditions. 301-300-0702 [email protected] 12-Month trading performance 10.0% S&P Current share price: $72.64 7.0% 52 wk range: $71.76 - $108.13 0.0% S5HLTH Market cap: $99.9bn 1.4% P/E: 6.8x (10.0%) XBI (3.0%) Diluted shares out.: 1.3bn Last dividend (9/4/2016): $0.47 (20.0%) GILD Dividend yield: 2.4% (25.5%) Beta: 0.94 (30.0%) EV/EBITDA: 4.8x EV/Sales: 3.1x (40.0%) Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Investment thesis We are placing a BUY rating on GILD with a price target of $92.00, a 20.4% upside to the current trading price.
    [Show full text]
  • Amgen-Opinion-Jan-7-2021.Pdf
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, Plaintiffs, v. Civil Action No. 20-0561-CFC HOSPIRA, INC. and PFIZER INC. Defendants. MEMORANDUM ORDER Having considered the merits of Defendants Hospira, Inc. and Pfizer Inc.' s Motion to Stay (D.I. 19) and the briefs filed by the parties in connection with that motion, it is HEREBY ORDERED that Defendants' motion to stay is GRANTED IN PART for the following reasons: 1. Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited make and sell the biologic filgrastim under the brand name Neupogen®. Filgrastim, like many biologics, is a protein. Plaintiffs own two patents generally related to methods of purifying such proteins. These two patents are U.S. Patent Nos. 10,577,392 (the #392 patent), and 9,643,997 (the #997 patent). The #392 patent issued in March of 2020. 2. Defendants manufacture and sell a biosimilar version Neupogen® called Nivestym®. Nivestym® has been available since 2018 and is the third biosimilar version ofNeupogen® launched in the United States since Neupogen® became available almost thirty years ago. 3. Both the #392 patent and #997 patent have been asserted against the Defendants-albeit in different actions-for the manufacture ofNivestym®. The #392 patent has been asserted in this case (C.A. 20-0561 ), which was filed on April 24, 2020. The #997 patent has been asserted in the related case Amgen Inc. et al. v. Hospira, Inc. et al., No. 18-cv-1064-CFC-CJB (D. Del. 2018). That case is scheduled for a jury trial to begin on May 17, 2021.
    [Show full text]
  • In the Supreme Court of the United States   ACORDA THERAPEUTICS, INC., Petitioner
    NO. 181280 In the Supreme Court of the United States ACORDA THERAPEUTICS, INC., Petitioner, v. ROXANE LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., and TEVA PHARMACEUTICALS USA, INC., Respondents. On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit BRIEF OF AMICUS CURIAE BOSTON PATENT LAW ASSOCIATION IN SUPPORT OF NEITHER PARTY SOPHIE F. WANG COUNSEL OF RECORD BRYANA T. MCGILLYCUDDY NATALIA SMYCHKOVICH CHOATE HALL & STEWART LLP TWO INTERNATIONAL PLACE BOSTON, MA 02110 (617) 248-5000 [email protected] MAY 8, 2019 COUNSEL FOR AMICUS CURIAE SUPREME COURT PRESS ʕ (888) 958-5705 ʕ BOSTON, MASSACHUSETTS i TABLE OF CONTENTS Page TABLE OF AUTHORITIES ....................................... ii INTEREST OF THE AMICUS CURIAE ................... 1 SUMMARY OF ARGUMENT .................................... 1 ARGUMENT ............................................................... 3 I. THE FEDERAL CIRCUIT’S DECISION CREATES SIGNIFICANT UNCERTAINTY CONCERNING THE SCOPE AND APPLICABILITY OF THE BLOCKING PATENT DOCTRINE. ............................................ 3 A. Clarification Is Needed as to the Definition of a “Blocking Patent.” .............. 3 B. Clarification Is Also Needed as to Whether and How the Blocking Patent Doctrine Should Be Applied to Objective Indicia of NonObviousness. ...................... 8 II. ABSENT CLARIFICATION, THE EXPANDED BLOCKING PATENT DOCTRINE HAS A CHILLING EFFECT ON INNOVATION AND INVESTMENT. .................. 11 A. Improvement Innovations Are Critical and Require Significant Investment. ....... 11 B. Objective Indicia Matter. .......................... 13 CONCLUSION .......................................................... 16 ii TABLE OF AUTHORITIES TABLE OF AUTHORITIES Page CASES Acorda Therapeutics, Inc. v. Roxane Labs., Inc., 903 F.3d 1310 (Fed. Cir. 2018) ......... passim Apple v. ITC, 725 F.3d 1356 (Fed. Cir. 2013) ......................... 14 Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990) ............................................. 6 Galderma Labs., L.P.
    [Show full text]
  • Views Expressed in This Publication by Any Contributor Are Not Necessarily Those of the Publisher
    THOMSON REUTERS Expansion of the blocking-patent doctrine By Ha Kung Wong, Esq., and Michael Scerbo, Esq., Venable LLP APRIL 13, 2020 In 2005 the U.S. Court of Appeals for the Federal Circuit first Therefore, the law considers two factors to be probative of articulated the blocking-patent doctrine in Merck & Co. v. Teva whether or not an invention would have been obvious: evidence Pharmaceuticals USA Inc., 395 F.3d 1364 (Fed. Cir. 2005), or of (1) commercial success, and (2) a causal nexus between the Merck I. invention and commercial success of a product embodying it.4 The Federal Circuit said that under the doctrine courts may reduce The Federal Circuit in Merck I explained that the district court’s the weight given to evidence of commercial success where an finding of commercial success should be given only minimal earlier patent blocked market entry by others. weight because Merck had both (1) a preexisting patent covering the administration of alendronate sodium (a bisphosphonate) to The appellate court later explained in Acorda Therapeutics treat osteoporosis, and (2) exclusive marketing rights granted by Inc. v. Roxane Laboratories Inc., 903 F.3d 1310 (Fed. Cir. 2018), the Food and Drug Administration. that a patent is a blocking patent “where the practice of a later invention would infringe the earlier patent.” ”Because market entry by others was precluded on those bases, the inference of nonobviousness … from evidence of commercial The rationale behind the doctrine was that where others are legally success … is weak.”5 barred from commercializing a purportedly obvious idea due to a preexisting patent, the court may conclude that the inference of In the years after the Federal Circuit’s decision in Merck I, the court nonobviousness from evidence of commercial success is weak.
    [Show full text]
  • In the United States District Court for the District of Delaware
    Case 1:20-cv-00561-UNA Document 1 Filed 04/24/20 Page 1 of 27 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, C.A. No. ________ Plaintiffs, v. HOSPIRA, INC. and PFIZER INC., DEMAND FOR JURY TRIAL Defendants. COMPLAINT Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited (collectively, “Plaintiffs”), by and through their undersigned attorneys, for their Complaint against Defendants Hospira, Inc. and Pfizer Inc. (collectively, “Defendants”) hereby allege as follows: THE PARTIES 1. Amgen Inc. is a corporation existing under the laws of the State of Delaware, with its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320. Amgen Inc. discovers, develops, manufactures, and sells innovative therapeutic products based on advances in molecular biology, recombinant DNA technology, and chemistry. Founded in 1980, Amgen Inc. is a pioneer in the development of biological human therapeutics. Today, Amgen Inc. is one of the largest biotechnology companies in the world, fueled in part by the success of NEUPOGEN® (filgrastim). 2. Amgen Manufacturing, Limited (“AML”) is a corporation existing under the laws of Bermuda with its principal place of business in Juncos, Puerto Rico. AML manufactures and sells biologic medicines for treating particular diseases in humans. AML is a wholly-owned subsidiary of Amgen Inc. Case 1:20-cv-00561-UNA Document 1 Filed 04/24/20 Page 2 of 27 PageID #: 2 3. On information and belief, Hospira, Inc. (“Hospira”) is a corporation existing under the laws of the State of Delaware, with its principal place of business at 275 North Field Drive, Lake Forest, Illinois 60045.
    [Show full text]
  • ANALYSIS of AGREEMENT CONTAINING CONSENT ORDERS to AID PUBLIC COMMENT in the Matter of Pfizer Inc
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT In the Matter of Pfizer Inc. and Hospira, Inc. File No. 151-0074 The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Pfizer Inc. (“Pfizer”) and Hospira, Inc. (“Hospira”) that is designed to remedy the anticompetitive effects resulting from Pfizer’s acquisition of Hospira. Under the terms of the proposed Consent Agreement, the parties are required to divest all of Pfizer’s rights and assets related to generic acetylcysteine inhalation solution and all Hospira’s rights and assets related to clindamycin phosphate injection, voriconazole injection, and melphalan hydrochloride injection to Alvogen Group, Inc. (“Alvogen”). The proposed Consent Agreement has been placed on the public record for thirty days for receipt of comments from interested persons. Comments received during this period will become part of the public record. After thirty days, the Commission will again evaluate the proposed Consent Agreement, along with the comments received, to make a final decision as to whether it should withdraw from the proposed Consent Agreement or make final the Decision and Order (“Order”). Pursuant to an Agreement and Plan of Merger executed on February 5, 2015, Pfizer proposes to acquire Hospira for approximately $16 billion (the “Proposed Acquisition”). The Commission alleges in its Complaint that the Proposed Acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, by lessening current competition in the markets for generic acetylcysteine inhalation solution and clindamycin phosphate injection and future competition in the markets for voriconazole injection and melphalan hydrochloride injection in the United States.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I
    Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I. Imaging Systems Corp A.L.I. Technologies (International) LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Pharmaceutical Products Group Abbott Point of Care Division Abbott Vascular Division Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Advanced Neuromodulation Systems, Inc. Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Alaven Pharmaceuticals, LLC 2260 Northwest parkway Suite A Marietta GA 30067 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allen Medical Systems, Inc. Allergan Sales, LLC Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Alpharma Pharmaceuticals, Inc. Alpharma Pharmaceuticals, LLC AMAG Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 AMATECH Corporation American Medical Distributors, Inc. 100 New Highway N Amityville NY 11701 American Medical System,
    [Show full text]
  • 2020 Annual Report 2020 PARTNER of the YEAR 3 Annual Comparison SUSTAINED, CONSISTENT GROWTH
    Greater Together Annual Report 2020 Greater Together The emergence of the COVID-19 pandemic led to unprecedented challenges for the global healthcare industry in 2020, and West played a vital role in the race to deliver an effective vaccine for the virus. CUSTOMERS: OUR PARTNERS Through these challenging times, vaccine developers have trusted West as a partner of choice to help protect their sensitive biomolecules. This is a testament to West’s almost 100 years of experience and reputation for leadership in quality. We have met these high expectations through our ability to flex our operations within our global network to meet supply needs. These customers were seeking components to support the development work, clinical trials, and potentially post-approval launches, and we have From the start of this global been committed to scaling production to meet their future volume requests. pandemic, we have had two In addition, West is also supplying primary packaging components for therapeutics used to treat COVID-19, as well as critical components that are priorities: first, ensuring the included in some of the diagnostic kit products that are being used to detect health and safety of our team COVID-19. members; and second, making We are committed to doing our part to provide for the large-scale manufacture of high-quality components required to serve customer needs for the delivery sure our customers have a reliable of a safe, effective COVID-19 vaccine. This has resulted in growing our global supply of the components that workforce to approximately 9,200 team members, expanding facility and equipment resources and shifting to 24/7 operating schedules at several sites are critical to the containment to address the demand for components associated with COVID-19.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • Brief in Opposition to Certiorari ______
    No. 19–1451 In the Supreme Court of the United States __________ SANOFI-AVENTIS DEUTSCHLAND, GMBH, PETITIONER v. MYLAN PHARMACEUTICALS INC., RESPONDENT __________ ON PETITION FOR A WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT __________ BRIEF IN OPPOSITION TO CERTIORARI __________ DOUGLAS H. CARSTEN STEFFEN N. JOHNSON Wilson Sonsini Counsel of Record Goodrich & Rosati, P.C. RICHARD TORCZON 12235 El Camino Real ADAM W. BURROWBRIDGE San Diego, CA 92130 Wilson Sonsini (858) 350–2300 Goodrich & Rosati, P.C. 1700 K Street, N.W. Washington, DC 20006 (202) 973–8800 [email protected] Counsel for Respondent QUESTIONS PRESENTED 1. Whether the Federal Circuit correctly conclud- ed that Sanofi, by failing to plead or otherwise raise a nonjurisdictional Appointments Clause challenge that was pleaded and briefed by dozens of other par- ties and was the subject of extensive public commen- tary, in any brief or at any time until a letter filed two months after oral argument in that court, forfeit- ed such a challenge to the underlying Patent Trial & Appeal Board ruling at issue. 2. Whether the Federal Circuit correctly affirmed the Patent Trial and Appeal Board’s fact-bound con- clusion that Sanofi’s patents were obvious because the purported invention—adding a nonionic surfac- tant to impede insulin glargine molecules from ag- gregating during storage—simply applied a known solution to a known insulin problem. ii RELATED PROCEEDINGS The following proceedings are directly related to the case: Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2017-01526 (P.T.A.B.), final written decision entered December 12, 2018.
    [Show full text]